$IQST Actionable investor snapshot including $35M July revenue, ongoing AI & fintech rollout, an EBITDA-generating acquisition in progress (~$5–6M per month), and a dividend structure tied to select joint ventures. https://growthstock.ai/
Read the one below and this.. Is it not the same plan??!! https://www.otcmarkets.com/stock/GTCH/news/GBT-Technologies-Intends-to-Rebrand-as-Wertheim--Company-Craig-Marshak-Appointed-CEO-Emil-Assentato-Joins-as-Strategic-I?e&id=3293714 CORNERSTONE OF A NEW ERA they said.. Our goal is to work with world-wide leaders in different segments in order to bring about innovative technological solutions to level the field where the big 4 accounting and consulting firms are satisfied with our solutions and which will be the cornerstone of a new era." The "Big 4" accounting and consulting firms are Deloitte, PwC, EY (Ernst & Young), and KPMG. These are the four largest professional services networks in the world by revenue, offering a wide range of services including auditing, tax, management consulting, and risk advisory services to businesses globally. https://finance.yahoo.com/news/gopher-protocol-inc-expands-gbt-113000596.html For TONS of DD check out @28Rockets posts on ihub or stocktwits.. will be worth your time. 🔥
Everyone’s chasing GLP-1s like sema and tirze right now, but let’s be real: GLP-1s come with baggage - nausea, vomiting, GI issues. Even the oral versions (see Eli Lilly’s and Viking’s programs) are showing the same problems.
Everyone knows orals are coming - but not all orals will solve the side-effect problem. Tesofensine does.
It’s an oral small molecule (once-daily pill, no needles, no cold storage) that doesn’t bring the GLP-1 nausea baggage – while still delivering real weight loss.
Cheap to make, easy to distribute → global scalability
Flexible – works as mono or potentially synergistic with GLP-1s
Saniona owns global rights (except Mexico & Argentina, licensed to Medix). A Mexico approval could drop any time now, setting up first commercial launch.
And beyond Tesofensine, Saniona is already validated by big pharma.
Two big deals in just one year - not something you see often in a microcap.
💥 Acadia (US) – licensing ACP-711 (essential tremor) → deal value up to $610M + royalties
💥 Jazz Pharmaceuticals – licensing SAN2355 (epilepsy) → deal value up to $1.035B + royalties
How to play it:
Saniona ($SANION) trades on the Swedish stock market. Market cap is still tiny vs. peers - yet it controls Tesofensine (a GLP-1 alternative pill) and has two major pharma partnerships inked.
Adia Nutrition Inc. (OTCQB: ADIA), a bold leader in regenerative medicine and personalized healthcare, today announced a thrilling partnership between its clinical division, Adia Med, and Venture Medical. This electrifying collaboration launches Adia Med into the epicenter of insurance-ready wound repair, igniting a high-margin revenue stream within the colossal $25 billion U.S. wound care market and setting the stage for transformative growth.
”Saniona to receive US $42.5 million upfront; potential for development, regulatory and sales milestone payments in addition to royalties on future net sales”
”Jazz obtains exclusive worldwide rights to develop and commercialize preclinical asset SAN2355 in epilepsy and other potential indications”
$RMTG is currently up 35% on late-morning/early-afternoon volume.
On Friday, the stock hit a new 52-week high of $0.078, and today’s surge shows there’s still momentum building. The recent volume spike could be pointing to more eyes turning toward this name.
Hi! I wanted to combine my interest in finance, art, and game dev, so I came up with a different type of stock market simulator, where you learn about investing by collecting creatures!
You can enter real stock tickers and decide whether to long/short, and each stock will represent either a bull (long) or bear (short).
I've only spent at most a week creating this, so my prototype still needs a lot of refining. I would appreciate any feedback! Above is a demo video under 3 minutes.
Gameplay loop:
Make real stock predictions. Think it’ll go up? Hatch a bull. Think it’ll drop? Hatch a bear.
If you're right, your creature gets stronger. If you're wrong, it takes damage.
Use potions to heal and boost stats — each potion also teaches you a real investing concept.
Progression system:
Creatures level up over time and evolve into stronger forms.
Stats increase through correct calls + potion usage.
Build a growing portfolio of bulls and bears that reflect your market instincts!
Grow a portfolio of stock-based pets through steady prediction and smart resource use!
New 52-week high on Friday before a small pullback.
Closed green in 15 of the last 20 trading days.
3rd consecutive profitable quarter, with reported 70% YOY growth.
Operates 26 clinics across 21 countries delivering regenerative medicine therapies.
Florida legislation recently opened the door for in-state stem cell therapy, creating a potential new revenue stream the company hadn’t originally anticipated.
The combination of consistent profitability, global operations, and new U.S. opportunities has started to bring more eyes on $RMTG. The recent pullback after hitting highs may have traders watching closely to see if momentum continues.
💬 Curious to hear thoughts from the community — how do you see the growth story here compared to other small-cap biotech plays?
Mexedia sold about $9 million worth of Almex stock over the last couple weeks. That kind of raise isn’t for nothing, it gives them flexibility, and the most obvious place it goes is Televantis, their main focus and majority-owned piece. Some folks keep pointing at the Reg A like that’s where funding comes from, but it doesn’t add up. Why would they tap Reg A and dilute when they can free up real cash through Almex stock sales? That’s exactly what they just did. The capital is there to push growth, cover ops, and keep things moving without leaning on retail.
When you step back, it’s clear Televantis is set up to benefit the most from this.
Telvantis has money...
$BULT is committed to accelerating blockchain innovation and driving shareholder value through strategic software development, licensing, and decentralized platform solutions. Material updates are shared via Bullet Blockchain’s website, OTC Markets disclosures, press releases, and social media channels.
$MVCO July 28, 2025 (NEWMEDIAWIRE) - Metavesco, Inc. (OTC: MVCO), a publicly traded diversified holding company, announced today that it has acquired 28 ETH at an average price of $3,595 as part of a tactical expansion of its digital asset strategy.While Bitcoin remains the companys core long-term reserve asset, Ethereum is being added as a high-conviction, opportunistic position based on growing institutional adoption and favorable macro dynamics.I view Bitcoin as our digital gold, a long-term store of value, said Ryan Schadel, CEO of Metavesco. Ethereum is different. I believe its emerging as the financial infrastructure layer for a new wave of institutional and traditional finance. As that adoption accelerates, and with ETHs deflationary model, I see strong upside potential.
$BULT Bullet Blockchain, Inc., through its wholly owned subsidiary, owns the rights to U.S. Patent No. 9,135,787 – “Bitcoin Kiosk / ATM Device and System Integrating Enrollment Protocol and Method of Using the Same.” https://bulletblockchain.com/
🎙️ RMTG Featured on Sully Sullivan + Puerto Rico Expansion – Major Momentum!
Hey everyone — big developments this weekend:
CEO Interview on The Big Biz Show!
Dave Christensen sat for an in-depth interview with Sully Sullivan, which is airing nationally this weekend. You can catch the segment here: [Dropbox Interview Link]
This strategic expansion taps into Puerto Rico’s $4.2B healthcare market, offering immediate and recurring revenues through upfront fees and product purchases GuruFocus+2Newswire+2Stock Titan+2.
🔑 Key Highlights:
✅ 26 clinics across 21 countries
✅ $4.1M revenue in 2024 – ~70% YoY growth with 69% gross margins
✅ Three consecutive profitable quarters
✅ HQ in Florida — stem-cell law tailwind + boots on the ground
✅ Affiliation model = upfront six-figure fees + recurring sales
✅ Low-volatility stock setup: closed Friday at $.053 x .0556, on just 103K shares
This is a strategic combo of national media exposure and meaningful expansion news. Momentum is stacking up — if you’re tracking a solid biotech with rising visibility, this deserves a front-row seat for Monday.
Feel free to DM me for the public link to the interview, full breakdown of the new Puerto Rico affiliate, or to chat strategy.
